Workflow
募集资金管理
icon
Search documents
国芯科技: 关于注销部分募集资金理财产品专用结算账户的公告
Zheng Quan Zhi Xing· 2025-07-21 13:08
证券代码:688262 证券简称:国芯科技 公告编号:2025-056 苏州国芯科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州国芯科技股份有限公司(以下简称"公司")于近日办理完成部分首次 公开发行股票募集资金理财产品专用结算账户的注销手续,现将相关事项公告如 下: 一、募集资金理财产品专用结算账户的设立情况 特此公告。 苏州国芯科技股份有限公司 董事会 | 开户人 | | 开户银行 | 银行账号 | 募投项目 | 账户状态 | | --- | --- | --- | --- | --- | --- | | | 江苏银行股份 | | 募集资金理 | | | | 苏州国芯科技 | | | 30260188000 | | | | | 有限公司苏州 | | 财产品专用 | 本次销户 | | | 股份有限公司 | | | 365171 | | | | 狮山支行 | | | 结算账户 | | | | | 中国银行股份 | | | | | | | | | 募集资金理 | | | | 苏州国芯科技 | 有限公司苏 ...
汇通控股: 关于签订募集资金专户储存三方监管协议的公告
Zheng Quan Zhi Xing· 2025-07-21 11:40
Summary of Key Points Core Viewpoint - Hefei Huitong Holdings Co., Ltd. has signed a tripartite supervision agreement for the storage of raised funds, ensuring compliance with regulations and protecting investor interests through proper management of the raised capital [1][2]. Group 1: Fundraising Overview - The company has received approval from the China Securities Regulatory Commission for its initial public offering, issuing 31,507,704 shares at a price of 24.18 RMB per share, raising a total of 761.8563 million RMB, with a net amount of 678.5604 million RMB after deducting issuance costs of 83.2959 million RMB [1]. - The raised funds were fully received by February 27, 2025, and verified by a certified public accountant [1]. Group 2: Tripartite Supervision Agreement - The tripartite supervision agreement was signed among Hefei Huitong Holdings, Wuhu Jinmei Auto Parts Co., Ltd., and Bank of China, along with the sponsor Zhongyin International Securities Co., Ltd. [2]. - The agreement stipulates that the raised funds must be used solely for the designated projects and not for any other purposes [2][4]. Group 3: Fund Management and Oversight - The agreement outlines the responsibilities of each party, with the sponsor (Zhongyin International Securities) conducting ongoing supervision of the fund usage and management [4][5]. - The sponsor has the right to perform on-site investigations and request information from the bank regarding the special account [4]. - The company is required to notify the sponsor of any expenditures exceeding 20% of the net raised funds promptly [4].
德联集团: 募集资金管理制度(2025年7月)
Zheng Quan Zhi Xing· 2025-07-21 11:35
广东德联集团股份有限公司 募集资金管理制度 第一章 总 则 第一条 为规范广东德联集团股份有限公司(以下简称"公司")募集资金 的管理和使用,提高募集资金的使用效率,防范资金使用风险,保护投资者的 利益,根据《中华人民共和国公司法》(以下简称《公司法》)、《中华人民共和 国证券法》(以下简称《证券法》)、《上市公司募集资金监管规则》(以下简称 《监管规则》) 、《深圳证券交易所股票上市规则》(以下简称《上市规则》)及 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 (以下简称《规范运作》)等有关法律、法规的规定,结合本公司实际情况,修 订本制度。 第二条 本制度所称募集资金,是指公司通过发行股票或者其他具有股权性 质的证券,向投资者募集并用于特定用途的资金,但不包括公司为实施股权激 励计划募集的资金监管;本制度所指超募资金是指实际募集资金净额超过计划 募集资金金额的部分。 第三条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业 政策和相关法律法规,践行可持续发展理念,履行社会责任,原则上应当用于 主营业务,有利于增强公司竞争能力和创新能力。募集资金不得用于持有财务 性投资 ...
聚灿光电: 关于公司2025年半年度募集资金存放与使用情况的专项报告
Zheng Quan Zhi Xing· 2025-07-21 10:31
Core Points - The report details the fundraising and usage status of 聚灿光电科技股份有限公司 for the first half of 2025, highlighting the total amount raised and how it has been allocated [1][2][5] Fundraising Overview - The company raised a total of RMB 108,560.00 million by issuing 118,000,000 shares at RMB 9.20 each, with actual funds received amounting to RMB 108,155.02 million after deducting issuance costs of RMB 404.98 million [1] - The funds were deposited into a dedicated account for management and oversight [1] Fund Usage and Balance - As of June 30, 2025, the company has utilized RMB 65,201.65 million of the raised funds, with a remaining balance of RMB 45,597.24 million [2][7] - The remaining funds include RMB 17,000.00 million in large-denomination certificates of deposit and RMB 20,000.00 million temporarily used to supplement working capital [2][7] Fund Management - The company has established a management system for the raised funds, ensuring safe, efficient, and transparent usage, in compliance with relevant regulations [2][4] - A tripartite supervision agreement was signed with banks to oversee the dedicated accounts for the raised funds [2][4] Project Investment - The funds have been allocated to specific projects, including RMB 5,509.71 million for the "Mini/Micro LED chip R&D and manufacturing expansion project" and RMB 14,935.08 million for the "Annual production of 2.4 million red and yellow light epitaxial chips project" [5][6] - The total investment in these projects amounts to RMB 20,444.79 million [5] Changes in Fund Usage - The company has not changed the intended use of the raised funds during the reporting period, maintaining compliance with the original investment commitments [5][6] - The company plans to extend the timeline for the "Mini/Micro LED chip R&D and manufacturing expansion project" to August 2026 [8]
军信股份: 中信证券股份有限公司关于湖南军信环保股份有限公司部分募投项目结项并将节余募集资金永久补充流动资金的核查意见
Zheng Quan Zhi Xing· 2025-07-21 09:15
中信证券股份有限公司(以下简称"中信证券")担任湖南军信环保股份有 限公司(以下简称"军信股份"或"公司")在深圳证券交易所创业板上市的保 荐人,根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上 市规则》《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等有关规定,就军信股份部分募投项目 结项并将节余募集资金永久补充流动资金的事项进行了审慎核查,具体情况如下: 一、募集资金基本情况 经中国证券监督管理委员会《关于同意湖南军信环保股份有限公司首次公开 发行股票注册的批复》(证监许可2022254 号)批准,并经深圳证券交易所同 意,公司首次公开发行人民币普通股(A 股)股票 6,834.00 万股,发行价格为每 股人民币 34.81 元,募集资金总额为人民币 2,378,915,400.00 元,扣除发行费用 人民币 113,783,770.20 元后,公司实际募集资金净额为人民币 2,265,131,629.80 元。募集资金已于 2022 年 4 月 8 日划至公司指定账户。天职国际会计师事务所 (特殊普通合伙)已于 2022 年 4 月 ...
森赫股份: 东吴证券关于森赫电梯股份有限公司部分募投项目结项并将节余募集资金永久补充流动资金的核查意见
Zheng Quan Zhi Xing· 2025-07-21 09:15
东吴证券股份有限公司 关于森赫电梯股份有限公司部分募投项目 结项并将节余募集资金永久补充流动资金的核查意见 东吴证券股份有限公司(以下简称"东吴证券"或"保荐机构")作为森赫 电梯股份有限公司(以下简称"森赫股份"或"公司")首次公开发行股票并在 创业板上市的保荐机构,根据《上市公司募集资金监管规则》《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关规定,对公 司部分募投项目结项并将节余募集资金永久补充流动资金事项进行了审慎核查, 核查意见如下: 一、募集资金基本情况 经中国证券监督管理委员会《关于同意森赫电梯股份有限公司首次公开发行 股票注册的批复》 (证监许可〔2021〕2313 号)同意注册,并经深圳证券交易所 同意,公司首次公开发行人民币普通股 66,696,667 股,每股面值 1 元,每股发行 价格为人民币 3.93 元,募集资金总额为 26,211.79 万元,扣除本次发行股票所支 付的承销、保荐费用、中介费、信息披露费等发行费用 4,537.79 万元(不含增值 税)后,实际募集资金净额为人民币 21,674.00 万元。 立信会计师事务所(特殊普通合伙)已于 ...
股市必读:天益医疗(301097)7月18日主力资金净流入373.63万元
Sou Hu Cai Jing· 2025-07-20 20:58
Group 1 - Tianyi Medical (301097) closed at 42.92 yuan on July 18, 2025, with an increase of 1.11% and a turnover rate of 6.02% [1] - The trading volume was 11,000 shares, with a total transaction amount of 47.0881 million yuan [1] - On the same day, the net inflow of main funds was 3.7363 million yuan, while the net outflow of speculative funds and retail investors was 2.8381 million yuan and 0.8982 million yuan, respectively [2][4] Group 2 - Tianyi Medical announced a change in the use of raised funds, terminating the "Comprehensive R&D Center Construction Project" of its subsidiary, Ningbo Tairis Technology Co., Ltd., and reallocating the remaining and over-raised funds to the "Thailand Production Base Construction Project" [2] - This change was approved by the shareholders' meeting on January 13, 2025, and the company has opened a special account for the raised funds at China Industrial Bank (Thailand) [2] - A five-party supervision agreement was signed to regulate the management of the raised funds, ensuring they are used solely for the "Thailand Production Base Construction Project" [3][4]
物产中大关于注销募集资金专户的公告
Fundraising Overview - The company raised a total of RMB 381,527.31 million through a non-public offering of 755,499,623 shares, with a net amount of RMB 379,898.67 million after deducting related expenses of RMB 1,628.64 million [1] - The funds were managed in accordance with the company's established fundraising management measures, ensuring investor rights protection [2] Fund Management and Usage - The company opened dedicated bank accounts for the management of the raised funds, adhering to regulatory requirements and signed agreements with the sponsor and banks [2] - The board approved the termination of several fundraising projects and the permanent allocation of surplus funds to working capital [3] Account Closure - As of the announcement date, the company had closed certain fundraising accounts, transferring a total of RMB 54,372.36 million to general accounts [5] Stock Incentive Plan - The company announced the listing of 37,980,750 shares under the 2021 restricted stock incentive plan, with the listing date set for July 24, 2025 [7][9] - The third lock-up period for the incentive plan has been fulfilled, allowing for the release of shares to 519 eligible participants [20] Legal Compliance - The company has obtained necessary approvals for the release of restricted shares and is required to fulfill information disclosure obligations [22]
科兴制药: 关于开立募集资金专项账户并签订募集资金专户存储三方监管协议的公告
Zheng Quan Zhi Xing· 2025-07-18 16:30
Fundraising Overview - The company has successfully completed its initial public offering (IPO) of 49.6753 million shares at a price of RMB 22.33 per share, raising a total of RMB 1,109,249,449, with a net amount of RMB 994,640,919 after deducting issuance costs [1][2] Fund Management and Regulatory Compliance - The company has established a special account for the management of the raised funds and signed a tripartite supervision agreement with the sponsor and the bank where the funds are deposited [2][3] - The agreement aims to ensure the proper use of funds for the "R&D Center Upgrade Project" and prohibits the use of these funds for any other purposes [3][4] Account Opening and Agreement Details - A new fundraising special account has been opened at China Postal Savings Bank, and the agreement includes provisions for the management and supervision of the funds [3][4] - The agreement specifies that the company can store part of the funds in deposits but cannot directly withdraw from these deposits [4][5] Supervision and Reporting - The sponsor is responsible for ongoing supervision of the fund management, including conducting at least biannual inspections of the fund's storage and usage [4][5] - The company must notify the sponsor of any significant expenditures from the special account and provide necessary documentation [5]
ST证通: 募集资金专项存储及使用管理制度(2025年7月)
Zheng Quan Zhi Xing· 2025-07-18 16:28
Core Viewpoint - The document outlines the management and usage of funds raised by Shenzhen Zhitong Electronics Co., Ltd, emphasizing the protection of investor interests and compliance with relevant laws and regulations. Group 1: General Principles - The management system is established to regulate the management and use of raised funds, ensuring investor interests are maximized [1] - The raised funds must be used for specific purposes as stated in the prospectus and related documents [1][3] Group 2: Fund Storage - The company must implement a special account storage system for raised funds, ensuring that these funds are not mixed with other funds [7] - A tripartite supervision agreement must be signed with the sponsor or independent financial advisor and the commercial bank within one month of the funds being in place [8] Group 3: Fund Usage Management - Fund expenditures must follow strict approval procedures, with plans proposed by relevant departments and approved by the financial head and chairman [9] - The company must ensure the authenticity and fairness of fund usage, preventing misuse by controlling shareholders or related parties [12] Group 4: Changes in Fund Usage - Any changes in the use of raised funds must be approved by the board of directors and disclosed to shareholders [23][24] - If the investment project is terminated or funds are left over, the company can change the use of those funds to permanently supplement working capital, following specific requirements [28] Group 5: Fund Management and Supervision - The accounting department must maintain detailed records of fund usage, and internal audits should occur quarterly [29][30] - The company must disclose any significant violations or risks in fund management to the board and the Shenzhen Stock Exchange [30][31]